Acute respiratory distress syndrome

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Veru Inc. - VERU

Retrieved on: 
Monday, January 9, 2023
Defense Department Advisory Committee on Women in the Services, News, Acute respiratory distress syndrome, Advisory Committee, COVID-19, Food, Patient, Pharmaceutical industry

NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. (“Veru” or the “Company”) (NASDAQ: VERU).

Key Points: 
  • NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. (“Veru” or the “Company”) (NASDAQ: VERU).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Veru and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

SeaStar Medical Submits Investigational Device Exemption (IDE) Application to FDA to Study a Novel Therapy to Reduce Hyperinflammation in Adult Acute Kidney Injury Patients

Retrieved on: 
Monday, January 9, 2023
AKI, Acute respiratory distress syndrome, COVID-19, Nephrology, Dialysis, Trial of the century, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, Safety, Manifest and latent functions and dysfunctions, Neutrophil, IDE, FDA, SCD, MD, HDE, Critical care, Economics, Homeostasis, Food, Patient, Monocyte, Mortality, Acute kidney injury, PMA, Jean-Louis Vincent, CKRT, SeaStar, Pharmaceutical industry

DENVER, Jan. 09, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical (Nasdaq: ICU), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, has submitted an investigational device exemption (IDE) application to the U.S. Food and Drug Administration (FDA) requesting approval to initiate a pivotal study to evaluate the effectiveness of the Company’s Selective Cytopheretic Device (SCD) in reducing hyperinflammation in adults with acute kidney injury (AKI) requiring continuous kidney replacement therapy (CKRT).

Key Points: 
  • Details of the study design will be provided upon IDE approval by the FDA.
  • “We are pleased to take this important step in our journey towards creating the new standard of care in reducing harmful hyperinflammation.
  • The FDA has demonstrated continued support in the SCD in granting breakthrough therapy status in adults and a substantive review of a Humanitarian Device Exemption (HDE) for pediatric AKI patients,” said Eric Schlorff, Chief Executive Officer of SeaStar Medical.
  • The SCD has demonstrated success in critically ill adult patients with AKI requiring CKRT, a condition with a high mortality rate.

MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast)

Retrieved on: 
Thursday, January 5, 2023
Mothers (Tokyo Stock Exchange), Food, Acute respiratory distress syndrome, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Tokyo Stock Exchange, AES, Sepsis, Cytokine release syndrome, Patient, Inflammation, HV, FDA, Code, Pharmaceutical industry

The trial results yielded encouraging findings as MN-166 (ibudilast) was delivered intravenously to HV with a favorable safety profile and was well tolerated.

Key Points: 
  • The trial results yielded encouraging findings as MN-166 (ibudilast) was delivered intravenously to HV with a favorable safety profile and was well tolerated.
  • There were no concerning adverse events (AEs), all reported AEs were mild, all study drug-related AEs were mild, and none of the AEs were unexpected.
  • This IV formulation of MN-166 (ibudilast) is being developed for inflammatory disorders, specifically prevention of acute respiratory distress syndrome (ARDS), sepsis, and cytokine release syndrome.
  • A parenteral formulation will expand the clinical utility of MN-166 by enabling the treatment of indications for which the oral formulation is not suitable.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Veru Inc. - VERU

Retrieved on: 
Sunday, January 1, 2023
Food, Acute respiratory distress syndrome, COVID-19, News, Defense Department Advisory Committee on Women in the Services, Patient, Advisory Committee, Pharmaceutical industry

NEW YORK, Jan. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. (“Veru” or the “Company”) (NASDAQ: VERU).

Key Points: 
  • NEW YORK, Jan. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. (“Veru” or the “Company”) (NASDAQ: VERU).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Veru and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Veru Inc. - VERU

Retrieved on: 
Sunday, December 25, 2022
Food, Acute respiratory distress syndrome, COVID-19, News, Defense Department Advisory Committee on Women in the Services, Patient, Advisory Committee, Pharmaceutical industry

NEW YORK, Dec. 24, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. (“Veru” or the “Company”) (NASDAQ: VERU).

Key Points: 
  • NEW YORK, Dec. 24, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. (“Veru” or the “Company”) (NASDAQ: VERU).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Veru and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Veru Inc. - VERU

Retrieved on: 
Thursday, December 15, 2022
Acute respiratory distress syndrome, Advisory Committee, Defense Department Advisory Committee on Women in the Services, Food, News, COVID-19, Patient, Pharmaceutical industry

NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. (“Veru” or the “Company”) (NASDAQ: VERU).

Key Points: 
  • NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. (“Veru” or the “Company”) (NASDAQ: VERU).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Veru and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Veru Inc. – VERU

Retrieved on: 
Thursday, December 8, 2022
Acute respiratory distress syndrome, Advisory Committee, Defense Department Advisory Committee on Women in the Services, Food, News, COVID-19, Patient, Pharmaceutical industry

NEW YORK, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. (“Veru” or the “Company”) (NASDAQ: VERU).

Key Points: 
  • NEW YORK, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. (“Veru” or the “Company”) (NASDAQ: VERU).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Veru and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Veru Inc. Investors to Inquire About Securities Class Action Investigation – VERU

Retrieved on: 
Monday, December 5, 2022
Titan, I-Space (Chinese company), Marcus Annius Verus (grandfather of Marcus Aurelius), Acute respiratory distress syndrome, Food, Advertising, News, Committee, COVID-19, Patient, Security (finance), Pharmaceutical industry

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=9728 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Global NAMPT Inhibitors Market Trends and Forecasts Research Report 2022-2040: Type of Molecule, Therapeutic Area, Indication, Route of Administration, Line of Treatment, and Key Regions - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 14, 2022
Biotechnology, Genetics, Health, Oncology, Molecule, Publication, Therapy, Acute respiratory distress syndrome, Social media, NAMPT, Partnership, Metabolism, Patient, Cancer, Type, Treatment, Research, Death, Hodgkin lymphoma, FDA, Investment, Attention, Administration, Growth, NAD, Degenerative disease, Acute myeloid leukemia, Non-Hodgkin lymphoma, Organization, Pharmaceutical industry

The "NAMPT Inhibitors Market, Distribution by Type of Molecule, Therapeutic Area, Indication, Route of Administration, Line of Treatment, and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2040" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "NAMPT Inhibitors Market, Distribution by Type of Molecule, Therapeutic Area, Indication, Route of Administration, Line of Treatment, and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2040" report has been added to ResearchAndMarkets.com's offering.
  • The "NAMPT Inhibitors Market" report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of NAMPT inhibitors in the healthcare domain, till 2040.
  • What are the strategic initiatives undertaken by players engaged in this market space related to research and development of NAMPT inhibitors?
  • How is the current and future market opportunity likely to be distributed across key market segments?

VERU ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Veru Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, December 7, 2022
Class Action Lawsuit, Professional Services, Legal, Fast Track, P.C, Standard of care, Acute respiratory distress syndrome, Aerospace, Tiberius Claudius Verus, Person, NDA, Health minister, Jeanne Eagels, Court, Patient, Death, FDA, Fast track (FDA), Form 10-Q, COVID-19, News, Trial of the century, Steiner, Breast, Safety, Telephone, EUA, Mortality, Prostate cancer, Infection, Prostate Cancer Foundation, Pharmaceutical industry, Renewable energy

Investors have until February 3, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until February 3, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Veru is primarily an oncology-based biopharmaceutical company that develops drugs for the management of breast and prostate cancers.
  • Veru had originally developed sabizabulin with the intention of using it as a treatment for prostate cancer.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.